


1436958



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

March 06, 2006

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/498,988

FILING DATE: August 29, 2003

RELATED PCT APPLICATION NUMBER: PCT/US04/27896

THE COUNTRY CODE AND NUMBER OF YOUR PRIORITY APPLICATION, TO BE USED FOR FILING ABROAD UNDER THE PARIS CONVENTION, IS US60/498,988



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

60498988

PTO/SB/16 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV 138172334 US

INVENTOR(S)

Given Name (first and middle (if any))	Family Name or Surname	Residence (City and either State or Foreign Country)
Paul S.	Cohen	Narragansett, Rhode Island

Additional inventors are being named on the _____ separately numbered sheets attached hereto

TITLE OF THE INVENTION (500 characters max)**LIVE ATTENUATED ALDOLASE-NEGATIVE BACTERIAL VACCINE**Direct all correspondence to: **CORRESPONDENCE ADDRESS**

<input checked="" type="checkbox"/> Customer Number:	31846
--	-------

OR

<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City		State		Zip	
Country		Telephone		Fax	

ENCLOSED APPLICATION PARTS (check all that apply)

<input checked="" type="checkbox"/> Specification Number of Pages <u>18</u>	<input type="checkbox"/> CD(s), Number _____
<input type="checkbox"/> Drawing(s) Number of Sheets _____	<input type="checkbox"/> Other (specify) _____
<input type="checkbox"/> Application Date Sheet. See 37 CFR 1.76	

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.	FILING FEE Amount (\$) \$160.00
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees.	
<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: <u>02-2334</u>	
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.	

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

<input checked="" type="checkbox"/> No.
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____

[Page 1 of 2]

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME William P. Ramey IIITELEPHONE 302 933 4034Date 8/29/2003REGISTRATION NO. 44,295

(if appropriate)

Docket Number: 1 2003.008 US PD**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Live attenuated aldolase-negative bacterial vaccine

The present invention relates to live attenuated bacteria for use in a medicament, to vaccines based upon such bacteria useful for the prevention of microbial pathogenesis, to the use of such bacteria for the manufacture of a vaccine and to methods for the preparation of such vaccines.

Immunity to microbial pathogenesis is one means by which a warm blooded animal avoids pathogenesis, or suffers a less intense pathogenic state. Incomplete immunity to a given pathogen results in morbidity and mortality in a population exposed to a pathogen. It is generally agreed that vaccines based on live but attenuated micro-organisms (live attenuated vaccines) induce a highly effective type of immune response. Such vaccines have the advantage that, once the animal host has been vaccinated, entry of the microbial pathogen into the host induces an accelerated recall of earlier, cell-mediated or humoral immunity which is able to control further growth of the organism before the infection can assume clinically significant proportions. Vaccines based on a killed pathogen (killed vaccine) are generally conceded to be unable to achieve this type of response. However, vaccines that contain a live pathogen present, depending on the level of attenuation, the danger that the vaccinated host upon vaccination may contract the disease against which protection is being sought.

Vaccines against bacteria belonging to e.g. the closely related families of Escherichia and Salmonella follow the general rules given above. Many members of these families of bacteria are pathogenic due to the fact that they infect the digestive tract and/or the bladder.

The pathogenic effect of these bacteria is closely related to their ability to colonise the mucosal layers of the digestive tract and/or the bladder. It is the phenomenon of colonisation that leads to the prolonged presence of the pathogen in the digestive tract and to a very close contact of the pathogen to the mucosal layers, which can also lead to invasion of other tissues. Thus, at the same time, paradoxically, it's due to the fact that these bacteria colonise the digestive tract and/or the bladder, and thus at the same time cause disease, that the immune system is triggered to develop a certain level of immune response. Consequently, this immune response is developed too late to suppress the pathogenic effect of the colonising bacteria.

It would be desirable to have a live attenuated vaccine against enteric infections, that possesses the immunising attributes of a live micro-organism but that is not capable of causing undesirable side effects upon vaccination.

A first prerequisite for such a vaccine would seem to be its ability to colonise the digestive tract.

5 It is the phenomenon of colonisation that provides a firm trigger of the immune system.

It is an objective of the present invention to provide a live attenuated bacterium that does provide protection against infection with wild-type bacteria.

10 Surprisingly it was found now that bacterial strains of the genus *Escherichia*, *Salmonella*, and *Yersinia* having a mutation in the *eda* gene that prevents the synthesis of functional Eda protein are very well capable of inducing a protective immune response against virulent wild-type bacteria in the host animal. Such mutants are, first of all, safe when used as live attenuated vaccine strains. Moreover, they are capable of preventing colonisation of wild type strains.

15 Merely as an example, when such vaccines are administered to chickens of over two weeks of age they are capable of inducing immunity even to the level that neither the vaccine strain nor the challenge strain can be re-isolated from the cloaca after challenge.

This is indeed against all expectations, since it has been shown that *E. coli* Eda-negative
20 mutants do not colonise the mouse large intestine (Sweeney, N.J. et al., in Infect. & Immun. 64: 3504-3511 (1996)). This is even the case if the mice are previously streptomycin-treated. Such treatment leads to the eradication of all facultative bacteria from the intestines, so that all possible intestinal niches are in principle available. Nevertheless, Eda-negative mutants were shown, contrary to their wild-type counterparts, to be unable to colonise in mice. Thus, Eda-
25 negative mutants were also not expected to colonise the digestive tract of other mammals or poultry, so they consequently were not expected to come into sufficiently close contact with the immune system to trigger it anyway.

Therefore, one embodiment of the present invention relates to a live attenuated bacterium that
30 is not capable to express a functional Eda protein as a result of a mutation in the *eda* gene, for use in a vaccine.

Additionally, *Eda*-mutants as described in the invention show a very low pathogenicity, which makes them attractive as vaccine strains.

5 The *eda* gene, encoding the Eda protein plays a key role in what is known as the Entner-Doudoroff Pathway. Its gene product, the Eda-protein is an enzyme, also known as KDPG-aldolase. This enzyme is used in the metabolism of glucuronate, galacturonate and gluconate. Fraenkel, D.G. has described the Entner-Doudoroff pathway in e.g. *E. coli* and *Salmonella* at p. 142-150 in F.C. Neidhardt, J.L. Ingraham, K.B. Low, B. Magasanik, M. Schaechter and H.E. Umbarger (ed.), *Escherichia coli* and *Salmonella typhimurium*: cellular and molecular biology. 10 American Society for Microbiology, Washington D.C. (1987). Egan et al., have analysed the Entner-Doudoroff pathway in *E. coli* and they have analysed the sequence and localized promoters for the *edd-eda* operon (Egan et al., J. Bacteriology 174: 4638-4646 (1992)).

15 The sequence of the DNA encoding Eda of *Salmonella typhimurium* is depicted in SEQ ID NO: 1. The sequence of the Eda protein itself is given in SEQ ID NO: 2.

20 The fact that *eda* mutants are not expected to colonise the digestive tract explains why, although such mutants were known in the art, they have never been suggested to be potential live attenuated vaccine candidates.

Due to its key position in carbohydrate metabolism, the *eda* gene and its gene product Eda are relatively widespread in the bacterial realm. The Eda protein is a highly conserved protein. It can be found in e.g. *Escherichia coli*, in *Salmonella* species, more specifically *Salmonella* 25 *enterica* species, such as serotype Typhimurium, Enteritidis and Dublin and in *Yersinia* species such as *Y. pestis*.

30 The mutation can be an insertion, a deletion, a substitution or a combination thereof, provided that the mutation leads to the failure to express a functional Eda protein. A functional Eda protein is understood to be a protein having the regulating characteristics of the wild-type protein. Thus, an Eda protein that is defective in at least one of its functions is considered to be a non-functional Eda protein. More specifically, a non-functional Eda protein would not or to a

lesser extent, when compared to its wild-type counterpart, be able to mediate the synthesis of KDPG from pyruvate and glyceraldehyde-3-phosphate and vice versa. As a result, a strain having a non-functional Eda-protein would not or to a lesser extent, when compared to its wild-type counterpart, be able to utilise glucuronate, galacturonate and gluconate.

5

Live attenuated bacteria for use according to the invention can be obtained in several ways. One possible way of obtaining such bacteria is by means of classical methods such as the treatment of wild-type bacteria having the *eda* gene with mutagenic agents such as base analogues, treatment with ultraviolet light or temperature treatment.

10

Strains that do not produce a functional Eda protein can easily be picked up. Such mutants can not utilise glucuronate, galacturonate or gluconate, but they can utilise glucose and galactonate.

They can therefore, on the basis of these specific abilities, very easily be selected *in vitro*. A detailed description of how to make such a selection has been described by Sweeney, N.J. et al., in Infect. & Immun. 64: 3504-3511 (1996).

The nature of a mutation if caused by classical mutation techniques is unknown. This may be a point mutation which may, although this is unlikely to happen, eventually revert to wild-type. In order to avoid this small risk, transposon mutagenesis would be a good alternative.

Mutagenesis by transposon mutagenesis, is also a mutagenesis-technique well-known in the art. This is a mutation accomplished at a localised site in the chromosome. Transposon-insertions can not be targeted to a specific gene. It is however very easy to pick up *eda*-mutants since they do not grow in vitro without nutrient compensation for lack of Eda activity.

Therefore, they can easily be selected from a pool of randomly transposon-mutated bacteria.

A much more attractive way of making mutations, i.e. the introduction of a mutation at a predetermined site, rather deliberately than randomly, is offered by recombinant DNA-technology. Such a mutation may again be an insertion, a deletion, a replacement of one nucleotide by another one or a combination thereof, with the only proviso that the mutated gene no longer encodes functional Eda. Such a mutation can e.g. be made by deletion of a number of base pairs. Even very small deletions such a stretches of 10 base pairs can already render

30

Eda non-functional. Even the deletion of one single base pair may already lead to a non-functional Eda, since as a result of such a mutation, the other base pairs are no longer in the correct reading frame. Each deletion or insertion of a number of base pairs indivisible by three causes such a frame shift. More preferably, a longer stretch is removed e.g. 100 base pairs.

5 Even more preferably, the whole *eda* gene is deleted.

It can easily be seen, that especially mutations introducing a stop-codon in the open reading frame, or mutations causing a frame-shift in the open reading frame are very suitable to obtain a strain which no longer encodes functional Eda.

All techniques for the construction of Eda-negative mutants are well-known standard
10 techniques. They relate to cloning of the Eda-gene, modification of the gene sequence by site-directed mutagenesis, restriction enzyme digestion followed by re-ligation or PCR-approaches and to subsequent replacement of the wild type *eda* gene with the mutant gene (allelic exchange or allelic replacement). Standard recombinant DNA techniques such as cloning the
15 *eda* gene in a plasmid, digestion of the gene with a restriction enzyme, followed by endonuclease treatment, re-ligation and homologous recombination in the host strain, are all known in the art and described i.a. in Maniatis/Sambrook (Sambrook, J. *et al.* Molecular cloning: a laboratory manual. ISBN 0-87969-309-6). Site-directed mutations can e.g. be made by means of in vitro site directed mutagenesis using the Transformer® kit sold by Clontech. PCR-techniques are extensively described in (Dieffenbach & Drexler; PCR primers, a
20 laboratory manual. ISBN 0-87969-447-3 and ISBN 0-87969-447-5).

The *eda* gene comprises not only the coding sequence encoding the Eda protein, but also regulatory sequences such as the promoter. The gene also comprises sites essential for correct translation of the Eda mRNA, such as the ribosome binding site.

25 Therefore, not only mutations in the coding regions but also mutations in those sequences essential for correct transcription and translation are considered to fall within the scope of the invention.

In a preferred embodiment, the invention relates to live attenuated bacteria of the genera
30 *Escherichia*, *Salmonella* and *Yersinia* for use in a vaccine.

In a more preferred form of the invention, the live attenuated bacterium according to the invention is selected from the group consisting of *S. enterica* serotype *typhimurium*, *enteritidis*, *choleraesuis*, *dublin*, *typhi*, *gallinarum*, *abortusovi*, *abortus-equi*, *pullorum*, *E. coli* or *Y. pestis*.

5 These bacterial genera comprise a large number of species that are pathogenic to both humans and a variety of different animals.

In an even more preferred form thereof, the live attenuated bacterium according to the invention is selected from the group consisting of *S. enterica* serotype *typhimurium*, *enteritidis*, *gallinarum*, *pullorum*, *E. coli* or *Y. pestis*.

10

Well-defined and deliberately made mutations involving the deletion of fragments of the *eda* gene or even the whole gene or the insertion of heterologous DNA-fragments or both, have the advantage, in comparison to classically induced mutations, that they will not revert to the wild-type situation.

15 Thus, in an even more preferred form, this embodiment of the invention refers to live attenuated bacteria in which the *eda* gene comprises an insertion and/or a deletion.

Given the large amount of vaccines given nowadays to both pets and farm animals, it is clear that combined administration of several vaccines would be desirable, if only for reasons of decreased vaccination costs. It is therefore very attractive to use live attenuated bacteria as a recombinant carrier for heterologous genes, encoding antigens selected from other pathogenic micro-organisms or viruses. Administration of such a recombinant carrier has the advantage that immunity is induced against two or more diseases at the same time. The live attenuated bacteria for use in a vaccine, according to the present invention provide very suitable carriers for heterologous genes, since the gene encoding the Eda protein can be used as an insertion site for such heterologous genes. The use of the *eda* gene as an insertion site has the advantage that at the same time the *eda* gene is inactivated and the newly introduced heterologous gene can be expressed (in concert with the homologous bacterial genes). The construction of such recombinant carriers can be done routinely, using standard molecular biology techniques such as allelic exchange.

20

25

30

Therefore, another embodiment of the invention relates to live attenuated recombinant bacteria, preferably of the genera *Escherichia*, *Salmonella* and *Yersinia* that do not produce a functional Eda protein and in which a heterologous gene is inserted, for use in a vaccine. Such a heterologous gene can, as mentioned above, e.g. be a gene encoding an antigen selected from other pathogenic micro-organisms or viruses. Such genes can e.g. be derived from pathogenic herpesviruses (e.g. the genes encoding the structural proteins of herpesviruses), retroviruses (e.g. the gp160 envelope protein), adenoviruses and the like.

Also a heterologous gene can be obtained from pathogenic bacteria. As an example, genes encoding bacterial toxins such as *Actinobacillus pleuropneumoniae* toxins, *Clostridium* toxins, outer membrane proteins and the like are very suitable bacterial heterologous genes.

Another possibility is to insert a gene encoding a protein involved in triggering the immune system, such as an interleukin or an interferon, or another gene involved in immune-regulation.

Insertion of the heterologous gene in the *eda* gene is advantageous, since in that case there is no need to find a new suitable insertion site for the heterologous gene, and at the same time the *eda* gene is knocked out.

Thus, in a preferred form of this embodiment the heterologous gene is inserted in the *eda* gene. The heterologous gene can be inserted somewhere in the *eda* gene or it can be inserted at the site of the *eda* gene while this gene has been partially or completely deleted.

Because of their unexpected attenuated but immunogenic character *in vivo*, the bacteria for use in a vaccine, according to the invention are very suitable as a basis for live attenuated vaccines.

Thus, still another embodiment of the invention relates to live attenuated vaccines for the protection of animals and humans against infection with a bacterium of which the wild type form comprises a *eda* gene.

Such vaccines comprise an immunogenically effective amount of a live attenuated bacterium for use in a vaccine, according to the invention or a live recombinant carrier bacterium according to the invention, and a pharmaceutically acceptable carrier.

Preferably, the vaccine comprises a live attenuated bacterium according to the invention, selected from the group of *Escherichia*, *Salmonella* and *Yersinia*.

Immunogenically effective means that the amount of live attenuated bacteria administered at vaccination is sufficient to induce in the host an effective immune response against virulent forms of the bacterium.

In addition to an immunogenically effective amount of the live attenuated bacterium described above, a vaccine according to the present invention also contains a pharmaceutically acceptable carrier. Such a carrier may be as simple as water, but it may e.g. also comprise culture fluid in which the bacteria were cultured. Another suitable carrier is e.g. a solution of physiological salt concentration.

- 5 above, a vaccine according to the present invention also contains a pharmaceutically acceptable carrier. Such a carrier may be as simple as water, but it may e.g. also comprise culture fluid in which the bacteria were cultured. Another suitable carrier is e.g. a solution of physiological salt concentration.
- 10 The useful dosage to be administered will vary depending on the age, weight and animal vaccinated, the mode of administration and the type of pathogen against which vaccination is sought.

The vaccine may comprise any dose of bacteria, sufficient to evoke an immune response.

- 15 Doses ranging between 10^3 and 10^{10} bacteria are e.g. very suitable doses.

Optionally, one or more compounds having adjuvant activity may be added to the vaccine. Adjuvants are non-specific stimulators of the immune system. They enhance the immune response of the host to the vaccine. Examples of adjuvants known in the art are Freund's

- 20 Complete and Incomplete adjuvant, vitamin E, non-ionic block polymers, muramyl dipeptides, ISCOMs (immune stimulating complexes, cf. for instance European Patent EP 109942), Saponins, mineral oil, vegetable oil, and Carbopol.

Adjuvants, specially suitable for mucosal application are e.g. the *E. coli* heat-labile toxin (LT) or *Cholera* toxin (CT).

- 25 Other suitable adjuvants are for example aluminium hydroxide, aluminium phosphate or aluminium oxide, oil-emulsions (e.g. of Bayol F (R) or Marcol 52 (R)), saponins or vitamin-E solubilisate.

Therefore, in a preferred form, the vaccines according to the present invention comprise an

- 30 adjuvant.

Other examples of pharmaceutically acceptable carriers or diluents useful in the present invention include stabilisers such as SPGA, carbohydrates (e.g. sorbitol, mannitol, starch, sucrose, glucose, dextran), proteins such as albumin or casein, protein containing agents such as bovine serum or skimmed milk and buffers (e.g. phosphate buffer).

- 5 Especially when such stabilisers are added to the vaccine, the vaccine is very suitable for freeze-drying. Therefore, in a more preferred form, the vaccine is in a freeze-dried form.

For administration to animals or humans, the vaccine according to the present invention can be given inter alia intranasally, intradermally, subcutaneously, orally, by aerosol or intramuscularly.

- 10 For application to poultry, wing web and eye-drop administration are very suitable.

The skilled person would know how to administer a vaccine according to the invention, because the method would most likely not differ from the methods followed for vaccination with presently existing bacterial vaccines. A vaccine according to the invention, especially when it comprises bacteria belonging to the family of *E. coli*, *Salmonella* or *Yersinia* would preferably be given

- 15 orally.

Still another embodiment relates to the use of a bacterium or a recombinant bacterium according to the invention for the manufacture of a vaccine for the protection of animals and humans against infection with a wild type bacterium or the pathogenic effects of infection.

20

Still another embodiment of the invention relates to methods for the preparation of a vaccine according to the invention. Such methods comprise the admixing of a live attenuated bacterium according to the invention or a live recombinant carrier bacterium according to the invention, and a pharmaceutically acceptable carrier.

25

EXAMPLES

Example 1

Construction of Eda-negative mutant.

The *eda* deletions were made using a modified Wanner method (PNAS June 6, 2000.

5 97(12):6640-45). Primers to the 5' and 3' *eda* flanking sequences of *S. enteritidis* SE5609 were designed with *Pst*I sites (*Pst*I *eda* 5': cta gct gca ggt gct aag cgg taa tct ggg and *Pst*I *eda* 3': cta gct gca gaa gag att gct cgt cat gtg g) and the PCR product was cloned into pBluescript SKII+ (pBSeda). *Bgl*II containing primers, to the *eda* promoter region (ctag aga tct ctgcctgattacta gtgtg) and the 3' end (ctag agatct aag ccg ttaaagcccgatgg) were used to reverse PCR amplify
10 the flanking and vector sequences from pBSeda. *Bgl*II digestion and subsequent ligation created an *eda* deletion clone called pBSedaΔ. A 1.2 kb *Bam*HI digested chloramphenicol resistant gene was inserted into the *Bgl*II site of pBSedaΔ to produce pBSedaΔcam. pBSedaΔcam was digested with *Pst*I and the insert was separated from vector sequences and used as the template for PCR. Eight 100 μl reactions were pooled, 5 μl was checked on a gel,
15 and the linear PCR product was ethanol precipitated and resuspended in 2-4 μl of water.

S. enteritidis SE5609 cells were electroporated with the temperature sensitive plasmid pKD46. When these cells are grown at 30°C in the presence of arabinose the plasmid expresses the lambda Red recombinase. The cells ($A_{600}=0.6$) were made competent for electroporation by
20 centrifugation and washing 3-4X with cold 10% glycerol. The linear PCR product was then electroporated into the competent cells. The recombinase acts to replace the wild type *eda* gene with the deleted *eda* gene containing the chloramphenicol cassette. SE5609 clones containing the deleted *eda* gene containing the chloramphenicol cassette were selected by overnight growth at 37°C on Luria agar plates containing chloramphenicol (30 μg/ml), which
25 also resulted in loss of the temperature sensitive pKD46 plasmid.

A different set of flanking *eda* 5' (ctagctgca gcc tca tat tcc gga cct gag c) and *eda* 3' (cta gct gca ggt gac ggt aaa agg cta atg cg) primers were used to verify one of the SE5609-*eda*⁽⁻⁾ *eda* mutants. An amplified fragment containing the wild type SE5609 *eda* gene produced a 927bp
30 band as expected, while the *eda* deletion/chloramphenicol mutant gave the expected 1677bp product. 1.8mM MgCl₂, with Finnzyme DyNAzymell polymerase was used in the reaction. Cycling conditions were 1X 94°C 4min; 30X 94°C 15sec, 55°C 30sec, 72°C 130sec; 1X 72°C

7min. In addition, the same SE5609-eda⁽⁻⁾ *eda* mutant was also confirmed by its inability to grow in liquid M9 minimal medium containing 0.2% (w/w) gluconate as the sole carbon source.

5 Example 2

Safety, vaccination- and challenge-tests.

Experimental design

To test both safety and efficacy, chickens were orally inoculated at 6 and 14 weeks of age with respectively 1.1×10^8 CFU and 4.1×10^8 CFU of SE5609-eda⁽⁻⁾.

10 Safety was assessed by clinical observation after vaccination. Also, cloaca swabs were taken at days 7 and 14 after each vaccination to determine the presence of the vaccine strain in the intestinal tract. Swabs were used to inoculate Brilliant Green Agars (BGA) directly and after enrichment in Rappaport Vassiliades Broth.

15 To test for efficacy, the vaccinated chickens and unvaccinated controls received an oral challenge infection with 1.3×10^8 CFU of a naladixic acid resistant wild-type S.e. strain at 16 weeks of age. Cloaca swabs were taken 3, 7 and 14 days after challenge to determine the rate of colonization by the challenge strain. Swabs were inoculated on BGA containing naladixic acid (BGAnal) directly and also after incubation in an enrichment medium (buffered peptone water containing nal).

20

Animals

Commercial laying hens were obtained from a Salmonella free flock.

Results

25 No clinical abnormalities were observed after both oral vaccinations.

First of all, the SE5609-eda⁽⁻⁾ strain was not cultured from cloacal swabs of the vaccinated animals on days 7 and 14, indicating that the strain was impaired in its ability to colonize the digestive tract of chickens.

30 Moreover, as shown in Table 1, vaccination with SE5609-eda⁽⁻⁾ resulted in a very significant reduction in colonization of the digestive tract by the challenge strain.

Table 1 Reisolation of the challenge strain from cloaca swabs

	S.e. (nal ^r) positive	
Day post challenge	SE5609-eda	Control
3	1/15 ^a	11/15
7	1/15 ^a	9/14
14	0/15	2/14

^a: significantly different from control ($p < 0.01$, Fisher exact test)

5 Conclusion: a vaccine based upon a *Salmonella enteritidis* eda⁽⁻⁾ strain which is a wild-type strain having eda⁽⁻⁾ as a single attenuation is safe. Moreover, vaccination with this *Salmonella enteritidis* eda⁽⁻⁾ strain resulted in complete prevention of colonization of the digestive tract by both the vaccine strain and the challenge strain.

Claims

- 1) Live attenuated bacterium of the genus *Escherichia*, *Salmonella* or *Yersinia*, said bacterium not being capable to express a functional Eda protein as a result of a mutation in the *eda* gene,
5 for use in a vaccine.
- 2) Live attenuated bacterium for use according to claim 1, wherein said bacterium is selected from the group consisting of *E. coli*, *Y. pestis*, *S. enterica* serotype *typhimurium*, *enteritidis*, *choleraesuis*, *dublin*, *typhi*, *gallinarum*, *abortusovi*, *abortus-equi*, *pullorum*.
10
- 3) Live attenuated bacterium for use according to claim 1 or 2, characterised in that the mutation comprises an insertion and/or a deletion.
- 4) Live attenuated bacterium for use according to claims 1-3, characterised in that said
15 bacterium carries a heterologous gene.
- 5) Live attenuated bacterium for use according to claim 4, characterised in that said heterologous gene is inserted in the *eda* gene
- 20 6) Live attenuated vaccine for the protection of animals or humans against infection with a pathogenic bacterium or the pathogenic effects thereof, characterised in that said vaccine comprises a bacterium as defined in claims 1-5 and a pharmaceutically acceptable carrier.
- 7) Live attenuated vaccine according to claim 6, characterised in that it comprises an adjuvant.
25
- 8) Live attenuated vaccine according to claim 6 or 7, characterised in that it is in a freeze-dried form.
- 9) Use of a live attenuated bacterium as defined in claims 1-5 for the manufacture of a vaccine
30 for the protection of animals against infection with a pathogenic bacterium or the pathogenic effects of infection.

10) Method for the preparation of a vaccine according to claims 6-8, characterised in that said method comprises the admixing of a live attenuated bacterium as defined in claims 1-5 and a pharmaceutically acceptable carrier.

ABSTRACT

The present invention relates to live attenuated bacteria for use in a medicament. The invention also relates to vaccines based upon such bacteria useful for the prevention of microbial pathogenesis and to the use of such bacteria for the manufacture of a vaccine. Finally, the
5 invention relates to methods for the preparation of such vaccines.

SEQUENCE LISTING

<110> AKZO Nobel N.V.

<120> live attenuated aldolase-negative bacterial vaccine

<130> eda

<160> 2

<170> PatentIn version 3.2

<210> 1

<211> 780

<212> DNA

<213> Salmonella typhimurium

<220>

<221> CDS

<222> (85)..(726)

<400> 1

aaaagctgtc ggggtgcggag cagggcgcaa cctgtatcac tttttaagat gacacactag 60

taatcaggcg	agagaagaat	tccg	atg	aaa	aac	tgg	aaa	aca	agt	gca	gaa		111
			Met	Lys	Asn	Trp	Lys	Thr	Ser	Ala	Glu		
			1				5						

gca	atc	ctg	acc	acc	ggc	ccg	gtt	gtc	ccg	gtc	att	gta	gtc	aat	aaa	159
Ala	Ile	Leu	Thr	Thr	Gly	Pro	Val	Val	Pro	Val	Ile	Val	Val	Asn	Lys	
10					15				20						25	

ctg	gag	cac	gcg	gtg	ccg	atg	gct	aaa	gcg	ctg	gtg	gcc	ggg	ggc	gtt	207
Leu	Glu	His	Ala	Val	Pro	Met	Ala	Lys	Ala	Leu	Val	Ala	Gly	Gly	Val	
				30				35						40		

cgc	gtt	ctg	gaa	gtg	act	tta	cgt	acg	gcc	tgc	gcg	atg	gat	gct	att	255
Arg	Val	Leu	Glu	Val	Thr	Leu	Arg	Thr	Ala	Cys	Ala	Met	Asp	Ala	Ile	
			45					50					55			

cgc	gct	atc	gct	aaa	gaa	gtg	ccg	gaa	gcg	att	gtc	ggc	gcc	gga	acc	303
Arg	Ala	Ile	Ala	Lys	Glu	Val	Pro	Glu	Ala	Ile	Val	Gly	Ala	Gly	Thr	
		60					65				70					

gtt	ctc	aat	ccg	cag	cag	ttg	gcg	gag	gtg	acg	gaa	gcg	ggc	gcg	caa	351
Val	Leu	Asn	Pro	Gln	Gln	Leu	Ala	Glu	Val	Thr	Glu	Ala	Gly	Ala	Gln	
	75					80					85					

ttt	gcg	att	agc	ccg	gga	ctg	act	gag	cca	ctg	ctg	aaa	gcc	gcg	acg	399
Phe	Ala	Ile	Ser	Pro	Gly	Leu	Thr	Glu	Pro	Leu	Leu	Lys	Ala	Ala	Thr	
90					95				100						105	

gca	ggc	act	atc	cca	ttg	att	ccc	ggt	att	agc	acc	gtt	tct	gaa	ctg	447
Ala	Gly	Thr	Ile	Pro	Leu	Ile	Pro	Gly	Ile	Ser	Thr	Val	Ser	Glu	Leu	
				110				115						120		

atg	ttg	ggc	atg	gac	tat	ggt	ctg	aaa	gag	ttc	aaa	ttc	ttc	ccg	gcg	495
Met	Leu	Gly	Met	Asp	Tyr	Gly	Leu	Lys	Glu	Phe	Lys	Phe	Phe	Pro	Ala	
			125				130						135			

gaa	gcg	aat	ggc	ggc	act	aaa	gcg	ttg	cag	gcg	att	gcc	ggt	ccg	ttc	543
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

Glu Ala Asn Gly Gly Thr Lys Ala Leu Gln Ala Ile Ala Gly Pro Phe
 140 145 150
 tct cag gta cgt ttc tgc cca act ggc ggc atc tct ccg gca aac tat 591
 Ser Gln Val Arg Phe Cys Pro Thr Gly Gly Ile Ser Pro Ala Asn Tyr
 155 160 165
 cgt gac tat ctg gcg ctg aaa agc gtg ttg tgc atc ggc ggt tcc tgg 639
 Arg Asp Tyr Leu Ala Leu Lys Ser Val Leu Cys Ile Gly Gly Ser Trp
 170 175 180 185
 ctg gtg ccg gcc gac gcg ctg gaa gcg ggt gat tac gat cgc atc acc 687
 Leu Val Pro Ala Asp Ala Leu Glu Ala Gly Asp Tyr Asp Arg Ile Thr
 190 195 200
 aaa ctg gcg cgc gaa gcg gta gaa ggc gcg aag cag taa gccgttaa 736
 Lys Leu Ala Arg Glu Ala Val Glu Gly Ala Lys Gln
 205 210
 gcccgatggc gcttgcttat cgggcttacg agtggcgatc aggc 780

<210> 2
 <211> 213
 <212> PRT
 <213> Salmonella typhimurium

<400> 2

Met Lys Asn Trp Lys Thr Ser Ala Glu Ala Ile Leu Thr Thr Gly Pro
 1 5 10 15
 Val Val Pro Val Ile Val Val Asn Lys Leu Glu His Ala Val Pro Met
 20 25 30
 Ala Lys Ala Leu Val Ala Gly Gly Val Arg Val Leu Glu Val Thr Leu
 35 40 45
 Arg Thr Ala Cys Ala Met Asp Ala Ile Arg Ala Ile Ala Lys Glu Val
 50 55 60
 Pro Glu Ala Ile Val Gly Ala Gly Thr Val Leu Asn Pro Gln Gln Leu
 65 70 75 80
 Ala Glu Val Thr Glu Ala Gly Ala Gln Phe Ala Ile Ser Pro Gly Leu
 85 90 95
 Thr Glu Pro Leu Leu Lys Ala Ala Thr Ala Gly Thr Ile Pro Leu Ile
 100 105 110
 Pro Gly Ile Ser Thr Val Ser Glu Leu Met Leu Gly Met Asp Tyr Gly
 115 120 125
 Leu Lys Glu Phe Lys Phe Phe Pro Ala Glu Ala Asn Gly Gly Thr Lys
 130 135 140

Ala Leu Gln Ala Ile Ala Gly Pro Phe Ser Gln Val Arg Phe Cys Pro
145 150 155 160

Thr Gly Gly Ile Ser Pro Ala Asn Tyr Arg Asp Tyr Leu Ala Leu Lys
165 170 175

Ser Val Leu Cys Ile Gly Gly Ser Trp Leu Val Pro Ala Asp Ala Leu
180 185 190

Glu Ala Gly Asp Tyr Asp Arg Ile Thr Lys Leu Ala Arg Glu Ala Val
195 200 205

Glu Gly Ala Lys Gln
210

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US2004/027896

International filing date: 26 August 2004 (26.08.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/498,988
Filing date: 29 August 2003 (29.08.2003)

Date of receipt at the International Bureau: 15 March 2006 (15.03.2006)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse